Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., February 16, 2023 — MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 fourth quarter and full year financial results on February 23, 2023, at 5:00 PM ET. The management will host a conference call to discuss these results and provide corporate updates. Presenters include CEO Michael Castagna and CFO Steven B. Binder. Interested parties can tune in via MannKind's website, with a replay available for 14 days. The company focuses on developing innovative therapeutic products for serious medical needs, particularly in endocrine and orphan lung diseases, utilizing dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD), focused on inhaled therapeutic products for endocrine and orphan lung diseases, announced that CEO Michael Castagna will participate in a Fireside Chat at the SVB Securities Global Biopharma Conference on February 15, 2023, at 1:40 pm (ET). Interested parties can access the live webcast through the Company’s website, with the replay available for 14 days post-event. MannKind aims to develop innovative therapies for conditions like diabetes and pulmonary arterial hypertension using advanced delivery systems.
MannKind Corporation (Nasdaq: MNKD) will present at the Lytham Partners Investor Select Conference on January 31, 2023, at 9:00 am ET. CEO Michael Castagna and CFO Steven B. Binder will participate in this virtual event, which aims to discuss the company’s innovations in inhaled therapeutic products for endocrine and orphan lung diseases. The presentation will be accessible on the company's website and archived for later viewing. Attendees can also engage in one-on-one meetings with management by contacting Lytham Partners.
MannKind focuses on meeting serious medical needs in diabetes and pulmonary diseases through advanced delivery systems.
MannKind Corporation (Nasdaq: MNKD) announced the advancement of clofazimine inhalation suspension (MNKD-101) to an adaptive Phase 2/3 study, paving the way for a potential treatment for nontuberculous mycobacterial (NTM) lung disease. Published findings highlight the product's tolerability and toxicokinetics, suggesting it could reduce systemic toxicity associated with oral treatments. An estimated 86,000-180,000 individuals in the U.S. suffer from NTM lung disease, which is on the rise. FDA has designated MNKD-101 as both an orphan lung and qualified infectious disease product (QIDP), indicating its potential significance in addressing this growing health concern.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 AM PST in San Francisco, California. Interested parties can listen to the webcast on the company's website, which will also be archived for replay. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, emphasizing rapid medicine delivery through their signature inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced promising results from the Afrezza with Basal Combination (ABC) Study, presented on November 10, 2022, at the Annual Diabetes Technology Meeting. Technosphere Insulin (TI) demonstrated a faster peak effect, occurring 30 minutes sooner, and significantly reduced postprandial glucose excursions at 60 minutes compared to subcutaneous insulins, with values of 57.9 mg/dL versus 101.4 mg/dL. No severe hypoglycemia was reported, highlighting TI's potential as a pump-sparing option for diabetes patients.
MannKind Corporation (MNKD) reported 3Q 2022 total revenues of $32.8 million, marking a 48% increase compared to 3Q 2021. Afrezza net revenue rose 11% to $10.8 million, with total revenues for the nine-month period reaching $63.7 million. The company experienced a 67% revenue growth in its Endocrine Business Unit, driven by Afrezza and V-Go demand. However, the net loss for 3Q 2022 was $14.4 million, reflecting increased SG&A and interest expenses. Gross profit for Afrezza improved to 81% margin compared to 61%
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
CEO Michael Castagna and CFO Steven Binder will discuss the results during a conference call, accessible via the company's website. MannKind focuses on innovative therapies for endocrine and lung diseases, utilizing advanced inhalation technologies. For further details, visit their official site.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company's webcast presentation will be available on September 28 at 9:00 am ET via its website. Additionally, management will hold virtual one-on-one meetings during the event. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, particularly utilizing advanced dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced the successful completion of a Phase 1 study on clofazimine inhalation suspension (MNKD-101) for treating nontuberculous mycobacterial (NTM) lung disease. The study indicated that the inhalation solution was well tolerated, with no serious adverse events or QT prolongation. The FDA has designated MNKD-101 as an orphan lung and qualified infectious disease product, addressing a high unmet medical need. MannKind plans discussions with the FDA regarding the findings and the ongoing clinical program.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
